Employees: 03 (2023.0)Legal category: SCA (commandite par actions)Size: PMECreation date: 2008-03-07 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: ATHIES-SOUS-LAON (02840), Aisne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELAS PHARMACIE CHARLEMAGNE : revenue, balance sheet and financial ratios
SELAS PHARMACIE CHARLEMAGNE is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in ATHIES-SOUS-LAON (02840),
this company of category PME
shows in 2023 a revenue of 3.0 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS PHARMACIE CHARLEMAGNE (SIREN 503028748)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
2 982 403 €
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
194 667 €
155 717 €
158 065 €
262 405 €
168 242 €
146 328 €
132 917 €
107 439 €
141 617 €
131 674 €
EBITDA
N/C
N/C
191 672 €
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
5.3%
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELAS PHARMACIE CHARLEMAGNE generates positive net income of 195 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 132 k€ -> 195 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
194 667 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 25%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 69%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
24.855%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
69.172%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
29.085
165.819
126.802
98.682
78.608
60.697
44.74
45.289
32.007
24.855
Financial autonomy
66.643
33.62
39.512
44.918
50.3
56.124
62.73
62.236
66.737
69.172
Repayment capacity
None
None
None
None
None
None
None
3.386
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
6.468%
None%
None%
Sector positioning
Debt ratio
24.862025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good-6 pts over 3 years
In 2025, the debt ratio of SELAS PHARMACIE CHARLEMAGNE (24.86) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
69.17%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of SELAS PHARMACIE CHARLEMAGNE (69.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
3.39 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of SELAS PHARMACIE CHARLEMAGNE (3.39) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 524.55. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
379.839
407.006
445.413
473.612
544.96
604.04
711.21
699.886
575.508
524.55
Interest coverage
None
None
None
None
None
None
None
2.391
None
None
Sector positioning
Liquidity ratio
524.552025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent
In 2025, the liquidity ratio of SELAS PHARMACIE CHARLEMAGNE (524.55) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
2.39x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of SELAS PHARMACIE CHARLEMAGNE (2.4x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELAS PHARMACIE CHARLEMAGNE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
0 €
413 629 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
0
28
0
0
Customer payment term (days)
0
0
0
0
0
0
0
8
0
0
Supplier payment term (days)
0
0
0
0
0
0
0
26
0
0
Positioning of SELAS PHARMACIE CHARLEMAGNE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELAS PHARMACIE CHARLEMAGNE is estimated at
3 092 308 €
(range 2 098 455€ - 4 852 257€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
2098k€3092k€4852k€
3 092 308 €Range: 2 098 455€ - 4 852 257€
NAF 5 année 2025
Valuation method used
Net Income Multiple
194 667 €
×
15.9x
=3 092 308 €
Range: 2 098 455€ - 4 852 258€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS PHARMACIE CHARLEMAGNE with other companies in the same sector:
Frequently asked questions about SELAS PHARMACIE CHARLEMAGNE
What is the revenue of SELAS PHARMACIE CHARLEMAGNE ?
The revenue of SELAS PHARMACIE CHARLEMAGNE in 2023 is 3.0 M€.
Is SELAS PHARMACIE CHARLEMAGNE profitable?
Yes, SELAS PHARMACIE CHARLEMAGNE generated a net profit of 195 k€ in 2025.
Where is the headquarters of SELAS PHARMACIE CHARLEMAGNE ?
The headquarters of SELAS PHARMACIE CHARLEMAGNE is located in ATHIES-SOUS-LAON (02840), in the department Aisne.
Where to find the tax return of SELAS PHARMACIE CHARLEMAGNE ?
The tax return of SELAS PHARMACIE CHARLEMAGNE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS PHARMACIE CHARLEMAGNE operate?
SELAS PHARMACIE CHARLEMAGNE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart